I. Pfupiso yeESMOGwaro re2025
Muna Nyamavhuvhu 2025, ESMO yakaburitsa zviri pamutemo gwaro reEarly and advanced non small cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow up, rakabudiswa mumagazini yepamusoro yeAnnals of Oncology. Iri ndiro bhuku rekutanga rakazara kubva muna 2017 uye rinopa ruzivo rwakasimba kune vanachiremba vekenza pasi rese.
Gomarara remapapu ndiro rine huwandu hwakanyanya hwezvirwere zvegomarara pasi rose. Gore rega rega, kune vanhu vanodarika mamiriyoni 2.2 vanobatwa negomarara uye vanhu vanopfuura mamiriyoni 1.8 vanofa, zvichiita kuti gomarara remapapu rive iro rinonyanya kukonzera rufu runokonzerwa negomarara muvarume nevakadzi. Gomarara remapapu risiri remasero madiki (NSCLC) rinobata vanhu vanosvika 80-85% yevarwere vese vane gomarara remapapu. Zvichienderana neizvi, kuburitswa kwegwara re2025 kunowedzera simba idzva resainzi mukurapa, nekuvandudzwa kwemaitiro ekuongorora biomarker kuri kwakakosha zvikuru.
II. Kududzirwa kweKuvandudzwa kweGwaro Rinokosha
2.1 Kuedzwa kweBiomarker: Kubva pa "Sarudzo" kuenda pa "Inokosha"
Gwaro re2025 rinoita shanduko huru panyaya yekuongororwa kwe biomarker. Gwaro iri rinotaura zvakajeka kuti kuongororwa kwe biomarker kwakakosha pakusarudza kurapwa kwevarwere vane danho re IB-III NSCLC.
Kurudziro iyi inowedzera kuongororwa kwemamorekuru kubva pakutarisa kwayakaita kare pavarwere vane chirwere chakanyanya kusvika padanho rekutanga, rinogona kubviswa. Chinangwa chikuru ndechekuona shanduko dzemajini dzinotungamira uye kupa hwaro hwesainzi hwekurapa kwakanyatsorongeka. Gwaro iri rinosimbisawo kuti kugona kwe biopsy uye nzira yekuongorora zvinofanirwa kusarudzwa nechikwata chevanhu vakawanda zvichienderana nehunhu hwemurwere uye bundu.
Nezvenzira chaiyo yekuyedza, gwara iri rinokurudzira zvakajeka kuti kuongororwa kwemajini kuitwe vasati vaita sarudzo dzekuvhiya, uye kuti kunofanira kunge kwakafukidza EGFR neALK. Pfungwa iyi ye "kuyedza pachine nguva" ine kukosha kukuru kwekiriniki kwekuparura kwakarurama uye kurapwa kwakagadzirirwa munhu wega kweNSCLC yekutanga - nguva uye kururama kwemhedzisiro yebvunzo zvinosarudza zvakananga sarudzo yekurapa kunotevera.
2.2 Kubudirira Mukurapa muDriver-Oncogene Positive Early-Stage NSCLC
Gwaro re2025 rinobatanidza humbowo kubva muzvidzidzo zvikuru zvekiriniki kuti rigadzire nzira yakajeka yekurapa varwere vane NSCLC yekutanga ine driver-oncogene positive.
Varwere vane EGFR-mutation positive:Zvichibva pamuedzo weADAURA wakakosha, mushure mekuvhiyiwa kwe adjuvant osimertinib kwemakore matatu yave chiyero chepasi rose chekutarisira varwere vane EGFR exon 19 deletions kana exon 21 L858R mutations. Muedzo weADAURA iongororo yepasi rose, ine nzvimbo dzakawanda, isina kurongeka, inodzorwa yechikamu chechitatu ichiongorora kushanda uye kuchengetedzeka kwe adjuvant osimertinib muvarwere vane NSCLC yakabviswa zvachose ye IB-IIIA EGFR-mutated. Chidzidzo ichi chakaratidza kuti osimertinib yakavandudza zvakanyanya kupona kusina chirwere uye kupona kwese zvichienzaniswa ne placebo, zvichiratidza kuti osimertinib ndiyo chiyero chitsva chekutarisira vanhu ava. Zvisinei, ongororo dzekuongorora dzemuyedzo weADAURA dzakaratidza kuti inenge 36% yekurega kurapwa kwekutanga kwakakonzerwa nezviitiko zvakaipa, uye imwe 31% yaive nekuda kwesarudzo yemurwere. Kuwanikwa uku kunoratidza kudiwa kwekuongororwa kwekutanga kwakarurama usati warapwa kuti uve nechokwadi chekuti kurapwa kwakanangana kunopiwa varwere vanogona kuwana rubatsiro runogara kwenguva refu.
Varwere vane ALK:Zvichibva paongororo yeALINA, adjuvant alectinib mushure mekuvhiyiwa kwemakore maviri ndiyo nzira yekutarisira varwere. Mukuongorora kwekutanga kweongororo yeALINA yechikamu chechitatu chakasarudzika, alectinib yakaratidza mukana wekurarama usina chirwere muchikamu chechipiri cheIIIA, ine huwandu hwengozi hwe0.24. Ruzivo rwakagadziridzwa kubva muongororo yeALINA rwakaunzwa pamusangano weESMO 2025 rwakaratidza kuti mushure memakore ≥3 ekutevera, mukana weDFS wealectinib wakaramba "uchienderera mberi uye uine chinangwa mukurapa," nechiyero chengozi che0.36 muchikamu chechipiri cheIIIA. Mwero wekurarama wemakore mana wazvino wakasvika 98.4%, mwero weDFS wemakore mana waive 75.5%, uye DFS yetsinga yepakati yakavandudzwawo, pasina zviratidzo zvitsva zvekuchengetedza. Ruzivo urwu rwakasimba runowedzera kusimbisa adjuvant alectinib senzira yekutarisira mushure mekubviswa kweALK-positive NSCLC uye runosimbisa kukosha kwekuongororwa kwakarurama kuti varwere vakadaro vaonekwe.
Sarudzo yenzira yekuyedza:Gwaro reESMO ra2025 rinotsanangura zvakajekakuyedzwa kwepaneru yeRT-PCR yakawandapamwe chete neRNA-based NGS, IHC, uye FISH seimwe yenzira dzehunyanzvi dzinokurudzirwa dzekuongorora ALK fusion. Izvi zvinoratidza kuti chinodiwa chikuru chegwara iri ndechekuita bvunzo dzinotungamira sarudzo dzekiriniki, pane kuraira puratifomu chaiyo yekuedza. Kune zvigadzirwa zveRT-PCR zvakanangana nekuona EGFR neALK, nzira iyi yekuedza inochinjika inopa chikonzero chakasimba chekushandisa kwadzo mukurapa.
III. Mhinduro dzehunyanzvi dzekuedza nemazvo
Gwaro re2025 rinoendesa bvunzo mberi kusvika padanho rekuita sarudzo dzisati dzaitwa kuvhiyiwa, izvo zvinoita kuti pave nepfungwa yekuti bvunzo dzakarurama, dzinonzwisisika, uye dzinogona kushandiswa. Zvigadzirwa zviviri zveRT-PCR-based detection zvinotsanangurwa pazasi zvinoenderana nezvinodiwa negwaro iri kubva pamaonero ehunyanzvi.
3.1 Kiti Yekuona Kushanduka kweEGFR - Puratifomu Yetekinoroji yeARMS Yakavandudzwa
Tekinoroji huru: Tekinoroji yeARMS yakagadziridzwa inobvumira kuwedzera kwakanangana kwematanho ekuchinja-chinja asina kuwanda zvakanyanya achipesana nemashure emhando yepamusoro.
Dziviriro nhatu dzehunyanzvi:
-Kuvandudzwa kweARMS → kunovandudza kuzivikanwa kwekuchinja kwemuviri
-Kuwedzera maEnzymatic → inogaya mamiriro ekunze emusango uye inovandudza magadzirirwo ezvakachinja
-Kuvharira tembiricha → kunoderedza kuwedzera kwete chaiko
KushandaKunzwisisa kwe1% mutant allele frequency
Kudzora kusvibiswa: Kudzora kwemukati kwakavakirwa mukati + enzyme yeUNG inodzivirira kusvibiswa
Nguva yekuchinja: Kushanda kwechubhu yakavharwa, inengeMaminetsi zana nemakumi maviri
Muenzaniso wekuenderana:Nyama/kuvhiyiwa kwemvuramienzaniso → inotaura nezvezvinodiwa "zvekuyedza pachine nguva"
Kufukidza:45 shandukomuEGFR exons 18-21, zvichinyatsoenderana nenzvimbo dzakaratidzwa gwara (exon 19 deletions uye exon 21 L858R)
Kushandiswa kwekiriniki: Inotungamira zvakananga kurapwa kweEGFR-TKI
3.2 MMT EML4-ALK Fusion Detection Kit – Mhinduro yeKuona Fusion Yakavakirwa paRNA
-Puratifomu yetekinoroji: RT-PCR yakavakirwa paRNA - inopa mabhenefiti aripo pamusoro penzira dzakavakirwa paDNA dzekuona fusion
-Kubatsira kwakavakirwa paRNA: Inoona zvakananga zvinyorwa zvakasanganiswa, zvichidzivirira zvinobudirira kusataura zvakaipa
-Dzidza humbowo: Mukubatanidzwa kweALK kushoma, RT-PCR yakavimbika zvakanyanya kupfuura bvunzo dzeDNA.
-Kunzwisisa: Inoona kusanganiswa kusvikaMakopi makumi maviri pakuita kwega kwega
-Kufukidzwa kwemhando dzakasiyana: MavharoMhando gumi nembiri dzekubatanidza EML4-ALK(kusanganisira musiyano 1 ~33%; musiyano 3a/3b pamwe chete ~29%)
-Kushanda & Kudzora kusvibiswa: Chubhu yakavharwa, ~maminitsi zana nemakumi maviri; zvinodzora maitiro akavakirwa mukati + enzyme yeUNG zvinodzivirira mhedzisiro yenhema
-Kuenderana kwezviridzwa: Inoenderana nemidziyo yakasiyana-siyana yePCR yenguva chaiyo
-Kurongeka kwenhungamiro: Inoenderana zvakanyanya negwara reESMO
IV. Kuenderana Pakati Pemiedzo Nenhungamiro Yekutungamira
Zvigadzirwa zviviri izvi zvinonyatsoenderana negwara reESMO 2025 rekutanga uye repamusoro-soro rekenza yemapapu isina masero madiki mune zvinotevera:
V. Mhedziso
Gwaro rekutanga reESMO 2025 reNSCLC rinounza nguva itsva yekuongorora nekurapa kwakarurama, kwakatarisana ne "kuyedza pachine nguva, kunanga zvakananga, uye kugadzirisa kurapwa."EGFR Mutation Detection Kit neMMT EML4-ALK Fusion Detection Kit zvinosangana nezvinodiwa negwara rezvinangwa, nguva, uye kururama kuburikidza nenzira dzakasiyana dzehunyanzvi."
Kiti yeEGFR inoshandisa tekinoroji yeARMS yakagadziridzwa pakuona shanduko dzakanangwa mumienzaniso mishoma, ichitsigira biopsy yenyama neyakagadzirwa nemvura kuti ikwanise "kuyedzwa pachine nguva."
Kiti yeALK yakavakirwa paRNA-based RT-PCR, ichipa mabhenefiti pamusoro penzira dzeDNA dzekuona fusion, zvichienderana nekurudziro yeESMO yemapaneru emultiplex RT-PCR ekuyedza ALK.
Pamwe chete, zvigadzirwa zviviri izvi zvinoumba mhinduro yekuyedza nemazvo inoenderana negwara reESMO 2025, zvichitsigira kurapa kweadjuvant kwakagadzirirwa munhu wega wega weNSCLC iri padanho rekutanga.
Mareferensi:
- Zer A, Ahn MJ, Barlesi F, nevamwe. Kenza yemapapu isiri masero madiki yakatanga uye yakakwira munharaunda: Gwaro reESMO Clinical Practice rekuongorora, kurapwa uye kuteverwa. Ann Oncol. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003
Nguva yekutumira: Chivabvu-06-2026